FDA Approves First-in-Class Daily Pill for Metastatic Pancreatic Cancer

By Arizona Asians Staff

The U.S. Food and Drug Administration has approved Rasonque, also known by its generic name daraxonrasib, as a new targeted treatment for certain adults with metastatic pancreatic cancer.

The approval, announced on August 26, 2026, marks a significant development for patients with pancreatic adenocarcinoma, one of the most aggressive and difficult-to-treat cancers.

A New Targeted Option

Rasonque is a once-daily tablet designed to target RAS proteins, which play a major role in driving tumor growth in many pancreatic cancers.

The FDA approved the drug for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Pancreatic adenocarcinoma accounts for the vast majority of pancreatic cancer cases in the United States. Because the disease is often detected late and can progress quickly, treatment options have historically been limited.

Clinical Trial Showed Longer Survival

The FDA said approval was based on a randomized clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma.

Patients who received Rasonque had a median overall survival of 13.2 months, compared with 6.7 months for patients who received standard chemotherapy.

That improvement gave regulators enough evidence to approve the treatment ahead of schedule, according to the FDA.

Hope for a Hard-to-Treat Cancer

The approval is being viewed as an important step because RAS-driven cancers have long been considered extremely difficult to target with medicine. For decades, researchers have worked to develop drugs that could safely and effectively interfere with the RAS pathway.

While Rasonque is not a cure, it provides a new treatment option for eligible patients facing advanced disease.

Patients Should Discuss Eligibility With Their Doctors

As with all cancer treatments, Rasonque may not be appropriate for every patient. Treatment decisions depend on cancer type, prior therapies, overall health, side effects, and physician guidance.

Patients and families should speak with an oncologist to understand whether this newly approved therapy may be suitable for their specific case.